Portfolio

Focusing on the Future of
Precision Health

At MEC, we believe the technologies created in this decade will lead to a golden age in innovation within the life sciences space. MEC invests in company creation, seed, Series A, and Series B opportunities where technology and novel approaches are transformative for patient care and directly address large, unmet needs. Our areas of focus include, but are not limited to:

AI to Advance Drug Discovery

The use of algorithms and advanced digital processing to find new, more effective therapies and reduce the cost of developing drugs.

Cell and Gene Therapy

The therapeutic methodologies designed to replace, inactivate, or introduce a new gene to treat disease. The transplantation of human cells to replace diseased or missing cells.

Precision
Medicine

Predictive, data-driven diagnostics or treatments in which prevention and care strategies are highly customized according to an individual’s genes, lifestyle, and environment.

Regenerative Medicine

Scientific methods designed to repair, regrow, or replace damaged or diseased cells, tissues, or organs.

Synthetic
Biology

Redesigning or re-engineering and assembling new biological systems by combining non-living and live biomolecular components.

OUR PORTFOLIO

Aspen Neuroscience
Active
Name: Aspen Neuroscience
Founded: 2018
Location: San Diego, CA
Stage: Series B
MEC Theme: Cell Therapy
Aspen Neuroscience

Headquartered in San Diego, Aspen Neuroscience, Inc. is a development stage, private biotechnology company focused on personalized cell therapies. The company is developing iPSCs to address diseases with high unmet medical need, beginning with autologous neuron replacement for both sporadic and genetic forms of Parkinson’s disease, and extending across the brain and central nervous system.

Immunitas Therapeutics
Active
Name: Immunitas Therapeutics
Founded: 2019
Location: Boston, MA
Stage: Series B
MEC Theme: AI/ML for drug discovery and development
Immunitas Therapeutics

Immunitas is a single cell genomics-based therapeutics company focused on immunology that is advancing multiple programs to the clinic. The company was founded by Longwood Fund with leading scientists from Dana-Farber Cancer Institute, Massachusetts General Hospital, the Broad Institute at Harvard, and MIT (Massachusetts Institute of Technology). Immunitas’ programs are derived from their platform, a cross-functional, highly integrated, single-cell genomics approach that enables rapid target identification and validation in parallel with antibody discovery and engineering. IMT-009, a first-in-class NK (Natural Killer) and T cell modulator targeting CD161, is being developed for the treatment of solid tumors and hematological malignancies. Immunitas is also advancing IMT-073, a dual-target NK and T cell modulator. Since being founded in 2019, Immunitas has raised a total of $97 million in venture funding from a strong syndicate of investors including Longwood Fund, Alexandria Ventures, Evotec, Leaps by Bayer, M Ventures, and Novartis Venture Fund (NVF).

www.immunitastx.com

Nobias Therapeutics
Active
Name: Nobias Therapeutics
Founded: 2020
Location: Philadelphia, PA
Stage: Series A
MEC Theme: AI/ML for drug discovery and development
Nobias Therapeutics

Nobias Therapeutics is a spinout from the Children’s Hospital of Philadelphia (CHOP) focused on artificial intelligence and machine learning-aided analysis of genotypes and clinical records to develop new therapies designed to cure illnesses in children. The company was founded in 2020 by MEC Managing Partner, Brian Halak, Dr. Hakon Hakonarson.  Dr. Hakonarson is the Founding Director of the Center for Applied Genomics and Endowed Chair in Genomics Research at the Children’s Hospital of Philadelphia and Professor of Pediatrics at the Perelman School of Medicine at the University of Pennsylvania. Nobias has two programs entering clinical trials that address the genetic basis of two different rare diseases in children. In addition, Nobias has launched discovery programs in a variety of rare and common diseases, thus creating a platform for therapeutic discovery.

www.nobiastx.com

Pleno
Active
Name: Pleno
Founded: 2017
Location: San Diego, CA
Stage: Seed
MEC Theme: Precision Medicine
Pleno

Pleno Inc. is an early-stage company developing a new innovative platform for highly sensitive genetic testing, such as monitoring minimal residual disease and early multi-cancer screening.  The platform will detect a diverse collection of analytical targets that includes DNA, RNA, and protein biomarkers with unprecedented speed and precision, and leverage advanced microfluidics to automate all aspects of sample preparation and analysis.

www.plenoinc.com

ProJenX
Active
Name: ProJenX
Founded: 2021
Location: New York City, NY
Stage: Company Creation/Seed
MEC Theme: Regenerative Medicine
ProJenX

ProJenX is a clinical-stage biopharmaceutical company developing novel small molecule therapeutics that target motor neuron degenerative pathways for the treatment of Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases. ProJenX is an MEC company creation effort in partnership with Project ALS, a nationally recognized nonprofit organization committed to ALS research. The company’s first product Prosetin is the first investigational drug developed by researchers at the Project ALS Therapeutics Core at Columbia as a potential treatment for ALS. It is an oral, brain penetrant, small molecule shown in multiple laboratory models of ALS to block MAP4 kinases, a specific group of protein kinases that we have shown to promote endoplasmic reticulum (ER) stress-mediated motor neuron loss in ALS models.

Rejuvitas
Active
Name: Rejuvitas
Founded: 2021
Location: New York City, NY
Stage: Company Creation/Seed
MEC Theme: Gene Therapy
Rejuvitas

Rejuvitas provides novel gene therapies employing metabolic reprogramming and regenerative medicine technologies developed in the lab of acclaimed geneticist, Stephen Tsang, M.D., PhD. The company is a MEC (Medical Excellence Capital) company creation founded along with Dr. Tsang, using IP licensed from Columbia University. In addition, Alexandria Technology Ventures has invested alongside. Rejuvitas is developing genetic and metabolic regenerative medicine therapies that address the underlying common cause of retinal degeneration and several significant neurodegenerative diseases. The lead program is targeting Retinitis Pigmentosa, a rare genetic disorder of the retina.

www.Rejuvitas.com